



celularity

THE NEXT EVOLUTION IN CELLULAR MEDICINE

Investor Presentation

June 2023



All statements in this presentation other than statements of historical facts regarding Celularity Inc. (“Celularity”) are “forward-looking statements” reflecting management’s current beliefs and expectations, including those relating to future events. In some cases, you can identify forward-looking statements by terminology such as “anticipate,” “believe,” “can,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “forecast,” “intends,” “may,” “might,” “outlook,” “plan,” “possible,” “potential,” “predict,” “project,” “seek,” “should,” “strive,” “target,” “will,” “would” and the negative of terms like these or other comparable terminology, and other words or terms of similar meaning. Many factors could cause actual results to differ materially from those described in these forward-looking statements, including but not limited to: the inherent risks in biotechnological development, including with respect to the development of novel cellular therapies, and the clinical trial and regulatory approval process; and risks associated with Celularity’s current liquidity, as well as developments relating to Celularity’s competitors and industry, along with those risk factors set forth under the caption “Risk Factors” in Celularity’s current annual report on Form 10-K filed with the Securities and Exchange Commission “SEC” and other filings with the SEC. Accordingly, forward-looking statements should not be relied upon as representing Celularity’s views as of any subsequent date, and Celularity undertakes no obligation to update forward-looking statements to reflect events or circumstances after the date hereof, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws. This presentation shall not constitute an offer to sell or the solicitation of an offer to buy securities, nor shall there be any sale of or securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such jurisdiction.

Celularity makes no representation or warranty as to the accuracy or completeness of the data contained herein and shall have, and accept, no liability of any kind, whether in contract, tort (including negligence) or otherwise, to any third party arising from or related to use of this presentation or the data contained herein. Certain information contained in this presentation relates to or is based on studies, publications, surveys and Celularity’s own internal estimates and research. Such estimates and research have not been verified by any independent source. In addition, market data which may be included in this presentation may involve a number of assumptions and limitations, and there can be no guarantee as to the accuracy or reliability of such assumptions.

Celularity owns or has the rights to various trademarks, service marks and trade names that it uses in connection with the operation of its business. This presentation may also contain trademarks, service marks, trade names and copyrights of third parties, which are the property of their respective owners. The use or display of third parties’ trademarks, service marks, trade names or products in this presentation is not intended to, and does not imply, a relationship with Celularity, or an endorsement or sponsorship by or of Celularity.

ABOUT CELULARITY

Celularity Inc. (Nasdaq: CELU) headquartered in Florham Park, N.J., is a biotechnology company developing placental-derived allogeneic cell therapies and advanced biomaterial-based therapeutics products.

- Our **IMPACT** platform capitalizes on the benefits of placental-derived stem, progenitor and immune cells to target multiple diseases and provides seamless integration, from bio-sourcing through manufacturing cryopreserved and packaged allogeneic cells at our purpose-built 150,000-square-foot facility.
- Our **cell therapy investigational products** — stem cell-derived unmodified and genetically modified natural killer (NK) cells, T-cells engineered with a CAR (CAR T-cells), and mesenchymal-like adherent stromal cells (MLASCs) — are the foundation of programs in cancer, autoimmune, infectious, immunological and degenerative diseases.
- Our **advanced biomaterial commercial products** target indications in degenerative diseases.
- A comprehensive and deep (>1,500) worldwide patent portfolio protects our platform, processes, applications and technologies.



CELULARITY'S VISION

Mission Statement



Deliver innovative off-the-shelf allogeneic cellular medicines and biomaterials for patients with high unmet need at unparalleled scale, quality and economics

Lead the transformative potential of placental-derived therapeutics:

advance the discovery of the placenta as an abundant, renewable source of advanced biomaterials and newborn cells, which are biologically preferred to cells from adult bone marrow or peripheral blood.

Target high value markets with high unmet need:


broad therapeutic applications including cancer, autoimmune, infectious, immunological and degenerative diseases.

Deliver off-the-shelf, affordable therapies:

cryopreserved allogeneic cellular medicines and biomaterial products that clinicians can access on demand and off-the-shelf, enabling repeat dosing/multiple cycles as typical of the outpatient setting.

CELULARITY: COMPANY HISTORY

Celgene Spin-out (2017) Leveraging 20+ Years of Cellular Therapeutics Innovation



2000 – Anthrogenesis Corporation – Founded by Dr. Robert Hariri
 2002 – Anthrogenesis acquired by Celgene, becomes Celgene Cellular Therapeutics
 2005 – Allogeneic Placental Mesenchymal-like Stromal Cells in Crohn's, DFU
 2016 – FIH allogeneic placental-derived NK cell therapy product (Placental NK-007)

KEY: CORPORATE MILESTONE CLINICAL MILESTONE FINANCIAL MILESTONE

OUR EXPERIENCED LEADERSHIP TEAM

With Deep Expertise in Cell Therapy and Advanced Biomaterials



Robert J. Hariri, M.D., Ph.D.
Chairperson, Founder, & CEO



John Haines
Senior EVP, GM & Chief
Administrative Officer



**Adrian Kilcoyne,
M.D., M.P.H., M.B.A.**
EVP & Chief Medical Officer



Stephen Brigido, DPM
President, Degenerative
Diseases




David Beers, CFA
Chief Financial Officer




CELULARITY PLACENTAL-DERIVED PRODUCT PLATFORM

Leveraging the Benefits of Placental-Derived Cells and Biomaterials to Target Multiple Diseases



One Placenta → Many Patients

- Universal donor material
- No requirement for matching between a patient and donor



Cryopreserved - On Demand & Off-The-Shelf

- No immunogenicity or toxicity
- Re-dose/fine tune treatments
- Absence of allo-antibodies




- **Postpartum Placenta**
 - Abundant, reliable, renewable and biologically consistent raw material
 - *Nature's 'professional' universal donor tissue*
 - +140 Million Worldwide
- **Unique Biological Properties**
 - Greater proliferative performance, and persistence
 - Greater natural immune tolerance
- **100-100K Doses/Placenta**
 - Unparalleled scalability

IMMUNOLOGICAL & DEGENERATIVE DISEASES


INFECTIOUS DISEASE

HEMATOLOGICAL & SOLID TUMOR CANCERS

AUTOIMMUNE DISEASES



SINGLE-SOURCE, PLACENTAL-BASED PLATFORM DRIVING BROAD PIPELINE



MANUFACTURING OVERVIEW

Fully Integrated, Purpose-Built Commercial Scale Manufacturing Site Including Translational Research & Biorepository



Purpose Built Facility for Commercial-scale Cellular Therapeutic Manufacturing

- \$80M investment in cGMP/cGTP manufacturing
- Enables greater control, efficiency and optimization than is achievable by outsourcing to contract manufacturing organizations (CMOs) alone

Staffed by Highly Specialized Scientists, Engineers & Technicians

- Optimized, product-specific CMC, QA/QC and manufacturing processes accelerate product development, production and commercialization
- Over 2 decades of experience with source material procurement

Commercial Scale, GMP-ready

- 9 Grade C/ISO 7 suites
- 6 Grade D/ISO 8 labs
- Dedicated translational research labs



Celularity benefits from Celgene's 15 year+ investment in developing the technologies and capabilities required to manufacture cellular products at scale with consistent and reliable quality

CELL THERAPY

Clinical Pipeline



				PRE-CLINICAL		CLINICAL	
Hematological Malignancies	Platform	Functionality	Indication	Discovery	IND-Enabling	Phase 1/2	Phase 2/3
CYNK-001	pNK	Unmodified	AML				
CYNK-301	pNK	IL15 + Marrow Homing + CAR	AML				
CYCART-19	pT	CD19 + TCR KO	NHL, MCL				
CYCART-201	pT	CD16 + TCR KO + mAb	NHL, MCL				
Solid Tumor	Platform	Functionality	Indication	Discovery	IND-Enabling	Phase 1/2	Phase 2/3
CYCART-201	pT	CD16 + TCR KO + mAb	HER2+ Tumors				
CYNK-302	pNK	CD16 + IL15 + CAR	NSCLC				
Autoimmune & Degenerative Disease	Platform	Functionality	Indication	Discovery	IND-Enabling	Phase 1/2	Phase 2/3
APPL-001	MLASC	TF KO	Crohn's Other potential indications				
pEXO-001	pEXO	Unmodified	Osteoarthritis				


DEGENERATIVE DISEASES

Advanced Biomaterial Products Pipeline



Degenerative Diseases	Indication	Discovery	Regulatory			Brands
Placental Connective Tissue Matrix	Integumental Tissue Replacement	●—————	361 HCT/P			Interfyl®
Amniotic Membrane Allograft	Wound Covering	●—————	361 HCT/P			BIOVANCE®
Tri-Layer Amniotic Membrane Allograft	Wound Covering	●—————	361 HCT/P			3L
Tri-Layer Amniotic Membrane Allograft	Protective Cover	●—————	361 HCT/P			Biovance 3L OCULAR
Connective Tissue Wrap	Tendon	●—————				
FUSE Bone Void Filler	Bone, Spine, Dental	●—————				
Degenerative Diseases	Indication	Preclinical	Regulatory	Phase 1	Phase 2	
Extracellular Matrix Particulates	Aesthetics	●—————				
Extracellular Particulate Matrix	Osteoarthritis	●—————				

CURRENT COMMERCIAL PORTFOLIO DEGENERATIVE DISEASES



Improving Patients Health with Placental-Derived Advanced Biomaterial Products

DEGENERATIVE DISEASE PORTFOLIO

Commercial Opportunities Deliver Revenue



- **Biovance®**: Intact, natural extracellular matrix that provides a foundation for the wound regeneration process and acts as a scaffold for restoration of functional tissue.
- **Biovance 3L**: a trilayer human amniotic membrane product focused on the ocular and surgical markets.
- **Interfyl®** human connective tissue matrix used by a variety of medical specialists to fill soft tissue deficits resulting from wounds, trauma, or surgery.

In the U.S.

- Celularity sales force
- Independent distributors

In the Middle East

- Exclusive distribution agreements
 - Saudi Arabia
 - United Arab Emirates, Qatar, Bahrain, Oman, Kuwait and Egypt



celularity

THE NEXT EVOLUTION IN CELLULAR MEDICINE